Brind.

Financial Comparison of Illumina and OmniAb

1 report, 1 independent Updated Thu 00:00

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A report compared the financial profiles of OmniAb and Illumina, noting differences in risk and ownership. OmniAb has a beta of 0.6, indicating lower volatility than the S&P 500, while Illumina has a beta of 1.41. Regarding ownership, 72.1% of OmniAb shares are held by institutional investors, compared to 89.4% for Illumina. Analyst recommendations show OmniAb has a consensus target price of $11.50, and Illumina has a consensus target price of $222.19.

From tickerreport.com

Why it matters

Some supportBrind's analysis of the reports

The comparison provides insight into the differing market perceptions and investment profiles of the two healthcare companies. Differences in volatility and institutional ownership may influence investor decisions regarding the companies' stock performance.

From tickerreport.com

Who's involved

IlluminaAmerican company that develops systems for the analysis of genetic variation, compared in the report

Keep exploring

The entities involved

Illumina
American company that develops systems for the analysis of genetic variation
- Illumina and eBay were discussed in the context of their economic moats.Fri 05:07
- Citigroup issued a rating report on Illumina, while MarketBeat aggregated the stock rating data.Wed 08:33

Related events

Illumina and MindWalk Holdings Corp. have partnered, with both companies operating in the field of AI-enabled drug discovery.Sep 3

Coverage

Newest first; wire copies grouped

Thu 00:00tickerreport.com